News | September 26, 2018

ARVINAS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING NEW HAVEN, Conn., Sept. 26, 2018 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening...

News | September 18, 2018

PRINCIPIA BIOPHARMA ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING AND FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARES SOUTH SAN FRANCISCO, Calif., Sept. 18, 2018 (GLOBE NEWSWIRE) — Principia Biopharma Inc. (Principia or the Company) (Nasdaq:...

News | September 18, 2018

HARPOON THERAPEUTICS ANNOUNCES APPOINTMENTS TO BOARD OF DIRECTORS AND MANAGEMENT TEAM Jonathan Drachman, M.D., former CMO of Seattle Genetics, Brings Immuno-Oncology Expertise to Board South San Francisco, CA – September 18, 2018 – Harpoon Therapeutics, Inc., a...

News | September 14, 2018

Aptinyx Presents Preclinical Data on NMDA Receptor Modulator NYX-2925 at the International Association for the Study of Pain’s 17th World Congress on Pain EVANSTON, Ill., Sept. 14, 2018 (GLOBE NEWSWIRE) — Aptinyx Inc. (NASDAQ:APTX), a clinical-stage...

News | September 18, 2018

Iterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections Remaining two of three planned Phase 3 pivotal trials now underway for Iterum’s lead antibiotic product...
dolor. luctus amet, felis ultricies velit, diam venenatis, mi, tristique